Van Vollenhoven R, Hahn BH, Tsokos GC, et al. Efficacy and Safety of Ustekinumab, an Interleukin 12/23 Inhibitor, in Patients with Active Systemic Lupus Erythematosus: Results of a Phase 2, Randomized Placebo-Controlled Study. ACR 2017, abstract 6L.
Bimekizumab behaalt als eerste primair eindpunt ASAS40-respons na 12 weken
jun 2018 | Spondyloartritis